J&J says apalutamide plus ADT cuts prostate cancer recurrence or death risk by 62% in PROTEUS substudy

Johnson & Johnson announced positive Phase 3 PROTEUS substudy results showing apalutamide plus androgen deprivation therapy reduced the risk of disease recurrence or death by 62% and the risk of metastasis or death by 51% versus radical prostatectomy alone in high-risk localized or locally advanced prostate cancer.

Detected & updated continuously · Source: Nebula